期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

美国生物防御药品疫苗研发机制与项目资助情况分析 被引量：4

US Biodefense Medical Countermeasures Research and Development Mechanism and Funding Analysis
下载PDF
导出
摘要 生物防御药品疫苗研发是生物防御能力建设的重要组成部分。本研究分析了美国生防药品疫苗研发机制、经费投入,以及针对炭疽、肉毒毒素中毒、鼠疫、天花、土拉热、出血热等的药品疫苗研发中美国卫生与公众服务部及国防部的项目资助情况,分析了其主要特点及启示。 Biodefense medical countermeasures research and development is an important part of biodefense ca-pacity building. In this study, the author analyzed the US biodefense medical countermeasures research and devel-opment mechanism, as well as anthrax, botulism, plague, smallpox, tularemia and haemorrhagic fever drug and vac-cine research and development funded by US Department of Health and Human Services and Department of De-fense, also its main characteristics and enlightenment for us were analyzed.
作者 田德桥
机构地区 军事医学科学院生物工程研究所
出处 《生物技术通讯》 CAS 2016年第4期535-541,共7页 Letters in Biotechnology
关键词 生物防御 药品 疫苗 研发机制 项目经费 美国 biodefense medical countermeasures research and development mechanism funding United States
分类号 R827.2 [医药卫生—临床医学]
  • 相关文献

参考文献3

二级参考文献170

  • 1Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon [J]. JAMA, 2001 , 285(8) : 1059 -1070.
  • 2Institute of Medicine/National Research Council. Globalization, Biosecurity, and the Future of the Life Sciences [ M ]. Washington DC: The National Academies Press, 2006.
  • 3National Research Council. Biotechnology Research in an Age of Terrorism [ M ]. Washington DC: The National Academies Press, 2004.
  • 4Smith TJ, Roxas-Duncan VI, Smith LA. Botulinum neurotoxins as biothreat agents [J]. J Bioterr Biodef, 2012, S7:003. doi: 10. 4172/2157 -2526. S7 -003.
  • 5Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon [J]. Crit Rev Microbiol, 2005, 31(1) :11 -18.
  • 6Wein LM, Liu YF. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk [ J ]. Proc Natl Aacd Sci USA, 2005, 102(28) : 9984 -9989.
  • 7Institute of Medicine/National Research Council. An International Perspective on Advancing Technologies and Strategies for Managing Dual-Use Risks [ M ]. Washington DC: The National Academies Press, 2005.
  • 8Knobler S, Mahmoud AF, Pray LA. Biological Threats and Terrorism: Assessing the Science and Response Capabilities: Workshop Summary (Second-Generation Botulinum Toxin Bioweapons) [ M]. Washington DC: The National Academies Press, 2002.
  • 9Webb RP, Smith TJ, Wright P, et al. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3 [ J ]. Vaccine, 2009, 27 (33) : 4490 - 4497.
  • 10Kiyatkin N, Maksymowych AB, Simpson LL. Induction of an immune response by oral administration of recombinant botulinum toxin [J]. Infect Immun, 1997, 65(11): 4586-4591.

共引文献60

同被引文献44

  • 1邹仲敏,赵吉清,程晋,但国蓉,姜帆,叶枫,董兆君.芥子气损伤防治药物的研究进展[J].中国药理学与毒理学杂志,2010,24(6):552-556. 被引量：3
  • 2邓敏捷,伍宁丰,梁果义,初晓宇,姚斌,范云六.一种新的有机磷降解酶基因ophc2的克隆与表达[J].科学通报,2004,49(11):1068-1072. 被引量：26
  • 3Bryden WA. DARPA Special Projects Office immune building program. [ EB/OL]. [ 2015 - 6 - 21 ] http://proceedings. ndia. org/5460/5460/l_bryden, pdf.
  • 4National Research Council. Protecting building occupants and operations from biological and chemical airborne threats: a frame- work for decision making[ M]. Washington DC:National Acade- mies Press ,2007.
  • 5Wood JP, Blair Martin G. Development and field testing of a mo- bile chlorine dioxide generation system for the decontamination of buildings contaminated with Bacillus anthracis [ J ]. J Hazard Mater,2009,164(2 -3) :1460 - 1467.
  • 6PP~Newswire. Coley ~anmeeutieal Group awarded defense department contract to develop CpG irrmmnostimulatory oligos for enhancement of vaccines [ EB/OL]. [2002 - 12 - 13 ] http ://www. prnewswire, corn/ news-releases/coley-pharmaceutical-group-awarded-defense-depa- rtment -eontmet-to-develop-cpg-immunostimulatory-oligos-for-enhanc- ement-of-vaecines-77145822, html.
  • 7Krieg AM. Therapeutic potential of Toll-like receptor 9 activation [ J ]. Nat Rev Drug Diseov,2006,5 (6) :471 - 484.
  • 8CIDRAP News. Anthrax vaccine maker wins NIAID grants [ EB/ OL] [2008 -7 -291. http://www, eidrap, umn. edu/news-per- spective/2008/07/anthrax-vaccine-maker-wins-niaid-grants.
  • 9Kang JH, Super M, Yung CW, et al. An extracorporeal blood- cleansing device for sepsis therapy[ J]. Nat Med ,2014,20(10) : 1211 -1216.
  • 10NIH News Release. NIH Funds next phase of tissue chip for drug screening program. [ EB/OL~ [ 2014 - 9 - 23 ]. http ://www. nih. gov/news/health/sep2014/ncats -23. htm.

引证文献4

二级引证文献2

生物技术通讯
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部